Rapamycin Plus Bevacizumab in Advanced Cancers

Part of paid clinical trials in Chicago, Illinois.

Sponsor
University of Chicago
Study ID
NCT00667485
Phase
PHASE1
Status
Completed

Conditions

  • Advanced Cancer
  • Metastatic Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Rapamycin (liquid) — DRUG
    Weekly Rapamycin (liquid) 90mg (dose will be split 45mg on Day 1 and Day 2 of each week)
  • Bevacizumab — DRUG
    Multiple doses (dose depends on time of study entry) given by IV once every 3 weeks
  • Rapamycin (Tablets) — DRUG
    Daily oral rapamycin (tablets) - 2 doses will be tested 4mg and 6mg

Study Details

The goal of this trial is to determine the toxicity and maximum dose of rapamycin and bevacizumab given together to subjects with advanced cancers. This study will also look at the pharmacokinetics and antitumor activity of the combination.

Key Dates

First listed
Apr 28, 2008
Start date
Apr 30, 2008
Status verified
Jan 2014
Primary completion
May 31, 2012
Completion
May 31, 2012

Study Design

Enrollment
28 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Weekly Rapamcyin
    Rapamycin (liquid) taken weekly and Bevacizumab (IV infusion ) once every 3 weeks
  • Experimental: Daily Rapamycin
    Daily oral rapamycin (tablets) and Bevacizumab (IV infusion)once every 3 weeks

Primary Outcome Measure

Toxicity [ Time Frame: 3 weeks ]

Locations (1)

FacilityCityStateZIPSite coordinators
University of ChicagoChicagoIllinois60637-

Find similar trials in Chicago, IL

By research site
University of Chicago· Chicago, IL

Related Studies